Facebook Icon Print Created with Sketch. Twitter Icon Created with Sketch. Created with Sketch. LinkedIn Icon Green Check Icon Created with Sketch. YouTube Icon Right Arrow Icon Mobile Menu Icon Chevron Right Icon Phone Icon Health Study Area: AutoImmune Disease Health Study Area: Blood Cancer Health Study Area: Cardiovascular Disease Health Study Area: Fibrosis Health Study Area: Gastrointestinal Cancer Health Study Area: Genitourinary Health Study Area: Head and Neck Cancer Health Study Area: Lung Cancer Health Study Area: Melanoma Health Study Area: Women's Cancer Health Study Area: Breast Cancer For Caregivers For Clinicians Communities FAQs For Parents For Patients Chevron Icon Bookmark Icon Map Icon Share Icon Direction Arrow Icon Direction Arrow Icon Page Icon Location Icon Search Icon External Link Icon Help Icon Error Icon Glossary Email Icon Gender Both Gender Male Gender Female Created with Sketch. Created with Sketch.

Please Log In/Join Now first, and then use this function!


A Study of CC-95251, a Monoclonal Antibody Directed Against SIRPα, in Subjects With Advanced Solid and Hematologic Cancers - CC-95251-ST-001

Updated: 16 February, 2021   |   ClinicalTrials.gov

Print Friendly Summary

Print this page and the trial guide to help you talk with your doctor.
Use the Study Participant's Guide to navigate the process of participating in a clinical trial. Understand key factors to consider before deciding and get questions to ask your healthcare team.

Trial Details

  • Phase 1


  • Gender(s)

  • 18+

    Age Range

  • 19


  • Recruiting

Treatment Options

Study Arms
Experimental: CC-95251 alone
Drug: CC-95251
Experimental: CC-95251 in combination with cetuximab
Drug: CC-95251 Drug: Cetuximab
Experimental: CC-95251 in combination with rituximab
Drug: Rituximab Drug: CC-95251

Key Eligibility Criteria

Inclusion Criteria: 1. Subject must understand and voluntarily sign an informed consent form (ICF). 2. Subject (male or female) is ≥ 18 years of age at the time of signing the ICF. 3. Subject must have progressed on (or not been able to tolerate due to medical comorbidities or unacceptable toxicity) standard anticancer therapy or for whom no other approved conventional therapy exists and have histological or cytological confirmation of advanced unresectable solid tumors. 4. Subject must have at least one site of measurable disease as determined by RECIST v1.1. NHL subjects must have bi-dimensionally measurable disease on cross sectional imaging by CT or MRI as defined by Lugano/IWG criteria. 5. Subject has an ECOG PS of 0 or 1. 6. Subjects must exhibit acceptable hematopoietic, liver, renal, and coagulation function as assessed by laboratory tests. 7. Subject is willing and able to adhere to the study visit schedule and other protocol requirements. Exclusion Criteria: 1. Subject has received prior investigational therapy directed at CD47 or SIRPα. 2. Subject has cancer with symptomatic central nervous system involvement. 3. Subject is on chronic systemic immunosuppressive therapy or corticosteroids. 4. Subjects with a history of clinically significant cardiac disease within the previous 6 months. 5. Subject had a prior systemic cancer-directed treatments or investigational modalities ≤ 5 half-lives or 4 weeks prior to starting CC-95251, whichever is shorter. 6. Subject had major surgery ≤ 2 weeks prior to starting CC-95251. 7. Subject is a pregnant or lactating female. 8. Subject has known human immunodeficiency virus (HIV) infection. 9. Subject has known chronic, active hepatitis B or C (HBV/HCV) infection. 10. Ongoing treatment with chronic, therapeutic dosing of anti-coagulants. 11. History of autoimmune hemolytic anemia or autoimmune thrombocytopenia. 12. History of concurrent second cancers requiring active, ongoing systemic treatment. 13. For subjects receiving cetuximab, known history of cetuximab intolerance.

We strongly recommend you contact BMS to report Side Effects (Adverse Events)
Side Effects (Adverse Events) and other reportable events are defined here
Report Side Effects (Adverse Events) or Product Quality Complaints: Medical Information

Have questions? Live support is available 24/7 - Call 855-907-3286 or email clinical.trials@bms.com

Have questions? Live support is available 24/7 -
Call 855-907-3286 or email clinical.trials@bms.com